
Attovia Therapeutics
ATTOPro trackingAttovia Therapeutics, Inc. · Nasdaq · Immune-disease biotechnology · Research source · 424B4 · Research as of 2026/08/05 · Latest filing · 10-Q · 2026-11-09 SEC ↗ · SEC checked 2026-11-21
Saved research available · 424B4
Attovia priced its IPO at $17.00 per share for 17.0 million shares, with Nasdaq listing approved under ATTO.
Updates and this research have separate source dates; newer facts do not silently replace earlier conclusions.
Newly listed — review valuation, deal quality and post-IPO supply before acting
A clinical-stage developer of ATTOBODY-based treatments for immune-mediated diseases. The IPO priced at $17.00 and raised $289.00M.
Full source-backed summary
A clinical-stage developer of ATTOBODY-based treatments for immune-mediated diseases. The IPO priced at $17.00 and raised $289.00M. The latest market-value reference is $895.00M; reported revenue is $1.35M and net result is $(64.13M). The offer figures are reconciled to the final prospectus.
- Business and development direction
A clinical-stage developer of ATTOBODY-based treatments for immune-mediated diseases.
Current business Immune-disease biotechnology100%
Future development Future direction not yet disclosed
Key risks
Risk 1
Clinical development, regulatory approval and cash-runway outcomes can change the equity value materially.
Risk 2
The latest reported period remains loss-making.
Risk 3
The primary-secondary mix, controlling holders and voting rights require the final beneficial-ownership table.
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Offering quality | This saved report has no compatible source inputs for this calculation. Open filing ↗ |
| # | Institution | Underwriting allocation | Ratio · calculated | Shares |
|---|---|---|---|---|
| 1 | Morgan Stanley & Co. LLC | 40.00% | 6,800,000 shares | |
| 2 | Leerink Partners LLC | 28.00% | 4,760,000 shares | |
| 3 | Citigroup Global Markets Inc. | 19.00% | 3,230,000 shares | |
| 4 | RBC Capital Markets, LLC | 7.00% | 1,190,000 shares | |
| 5 | LifeSci Capital LLC | 6.00% | 1,020,000 shares |
Ratio = institution commitment ÷ complete source-table total (17,000,000 shares) × 100.
Underwriting terms
| Measure | Reported value | Unit |
|---|---|---|
| Underwriting discount per share | $1.19 | $ / share |
| Total underwriting discount | $20,230,000 | $ |
Source and calculation
Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 4; source 3062:5754; SHA256 858bad04ffdb44b28bdcc16e85880f0b8bb111f8fe961ad907d6e54e627e5e2b ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 4; source 3062:5754; SHA256 858bad04ffdb44b28bdcc16e85880f0b8bb111f8fe961ad907d6e54e627e5e2b ↗IPO CAPITAL QUALITY
Basis and evidence
No estimate is substituted for missing offer terms.
Capital quality is not yet quantifiable from the filed terms. IPO177 will calculate it when primary/secondary shares, fees and net proceeds are all disclosed.
Offering structure
| Measure | Reported value | Unit |
|---|---|---|
| Shares offered | 17,000,000 | Shares |
| Offering price | $17 | $ / share |
| Gross offering amount | $289,000,000 | $ |
Source and calculation
Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.
Prospectus offering table; stated base scenario and source conditions
SEC table 40 row 2; source 92131:97654; SHA256 420bd74618131df6b7ffaeb4006cd07d0ca5a66059d442ab11fdba29f9e44553 ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 3; source 3062:5754; SHA256 858bad04ffdb44b28bdcc16e85880f0b8bb111f8fe961ad907d6e54e627e5e2b ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 3; source 3062:5754; SHA256 858bad04ffdb44b28bdcc16e85880f0b8bb111f8fe961ad907d6e54e627e5e2b ↗Proceeds and intended uses
| Measure | Reported value | Unit |
|---|---|---|
| Issuer proceeds before expenses | $268,770,000 | $ |
Source and calculation
Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 5; source 3062:5754; SHA256 858bad04ffdb44b28bdcc16e85880f0b8bb111f8fe961ad907d6e54e627e5e2b ↗Dilution and valuation
| Calculation | Shares | Value | Reference |
|---|---|---|---|
| Base post-offer valuation | ≈ 43.029M | ≈ $731.4933M | |
| Post-offer shares — base/no option | 43,029,017 | — | |
| Post-offer shares — full option | 45,579,017 | — | |
| Capitalization shares — actual | 4,511,041 | — | |
| Capitalization shares — pro forma | 26,029,017 | — | |
| Capitalization shares — pro forma as adjusted | 43,029,017 | — | |
| Shares offered | 17,000,000 | — | |
| Offering price | — | $17 | |
| Gross offering amount | — | $289,000,000 |
Basis and evidence ↗
Prospectus share summary; Common stock to be outstanding immediately after this offering; 43,029,017 shares (or 45,579,017 shares, if the underwriters exercise their over-allotment option in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Prospectus share summary; Common stock to be outstanding immediately after this offering; 43,029,017 shares (or 45,579,017 shares, if the underwriters exercise their over-allotment option in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Capitalization share count; source stage: actual; Common stock, par value $0.0001 per share; 284,023,000 shares authorized, 4,511,041 shares issued and outstanding, actual; 500,000,000 shares authorized, 26,029,017 shares issued and outstanding, pro forma; 500,000,000 shares authorized, 43,029,017 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator
Figures retain their stated source scenario and conditions.
Capitalization share count; source stage: pro forma; Common stock, par value $0.0001 per share; 284,023,000 shares authorized, 4,511,041 shares issued and outstanding, actual; 500,000,000 shares authorized, 26,029,017 shares issued and outstanding, pro forma; 500,000,000 shares authorized, 43,029,017 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator
Figures retain their stated source scenario and conditions.
Capitalization share count; source stage: pro forma as adjusted; Common stock, par value $0.0001 per share; 284,023,000 shares authorized, 4,511,041 shares issued and outstanding, actual; 500,000,000 shares authorized, 26,029,017 shares issued and outstanding, pro forma; 500,000,000 shares authorized, 43,029,017 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator
Figures retain their stated source scenario and conditions.
Prospectus offering table; stated base scenario and source conditions
Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
completion-of-this-offering
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 43,029,017 shares (or 45,579,017 shares, if the underwriters exercise their over-allotment option in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Exact input · Offering price: $17
Exact input · Post-offer shares — base/no option: 43,029,017
Prospectus share summary; Common stock to be outstanding immediately after this offering; 43,029,017 shares (or 45,579,017 shares, if the underwriters exercise their over-allotment option in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value
Exact input · Post-offer shares — full option: 45,579,017
completion-of-this-offering
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 43,029,017 shares (or 45,579,017 shares, if the underwriters exercise their over-allotment option in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
completion-of-this-offering
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 43,029,017 shares (or 45,579,017 shares, if the underwriters exercise their over-allotment option in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Prospectus share summary; Common stock to be outstanding immediately after this offering; 43,029,017 shares (or 45,579,017 shares, if the underwriters exercise their over-allotment option in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 43,029,017 shares (or 45,579,017 shares, if the underwriters exercise their over-allotment option in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Exact input · Post-offer shares — base/no option: 43,029,017
Exact input · Offering price: $17
Share-count comparison
A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.
Source ↗IPO valuation scenario simulator
Offering completion · $17 × ≈ 43.029M shares · Final
Source and calculation ↗
Reported point prices retain their security, class, currency and per-security unit; range endpoints remain separate.
Reported whole-issuer base counts retain explicit option, conversion and surrender assumptions.
Equity value is the exact product of the selected compatible per-share price and whole-issuer post-offer count.
A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.
Each reported full-option, actual, diluted or class-specific case remains independent; no class sum or cross-date substitution is inferred.
The exact selected base supports transparent hypothetical price/share changes; it is not a forecast or tradable float.
The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.
These saved displays are not verified valuation inputs. Their stage, precision and assumptions have not been established by the current source.
IPO price · 17.000M · $289.00M · $17.00
Latest shares outstanding · 43.03M · $895.00M · Market snapshot
Revenue reference · — · $1.35M · Not meaningful
Net-result reference · — · $(64.13M) · Loss-making
$17 × 43,029,017 = $731,493,289 [summary-table-40-base-6-price, summary-table-40-base-6-post]
Exact calculation · Derived whole-issuer equity value: $731,493,289
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Ownership across stages | Comparable ownership figures across stages are unavailable in this report. See Control for holdings on their disclosed basis. Open filing ↗ |
Latest available filing
- Economic
- ~39.5%*
- As of
- 2026/08/05
Relationship filters
Select for details · Attovia Therapeutics
Holdings and voting rights
Holder groups may overlap; these rows are not an additive ownership partition.
| Holder / measure | Shares | Ownership | Voting rights | Reference |
|---|---|---|---|---|
| Frazier Life Sciences XI, L.P.Beneficial shares | 5,565,980 | — | — | Number ofSharesBeneficiallyOwned |
| Alamar HoldCo, LLCBeneficial shares | 3,229,279 | — | — | Number ofSharesBeneficiallyOwned |
| venBio Global Strategic Fund IV, L.P.Beneficial shares | 3,799,016 | — | — | Number ofSharesBeneficiallyOwned |
| Entities affiliated with Goldman Sachs & Co. LLCBeneficial shares | 2,435,641 | — | — | Number ofSharesBeneficiallyOwned |
| Deep Track Biotechnology Master Fund, LtdBeneficial shares | 1,957,139 | — | — | Number ofSharesBeneficiallyOwned |
| Tao FuBeneficial shares | 893,456 | — | — | Number ofSharesBeneficiallyOwned |
| Petter VeibyBeneficial shares | 212,258 | — | — | Number ofSharesBeneficiallyOwned |
| Hubert ChenBeneficial shares | 153,279 | — | — | Number ofSharesBeneficiallyOwned |
| Mitchell GoldBeneficial shares | 41,873 | — | — | Number ofSharesBeneficiallyOwned |
| Angie YouBeneficial shares | 59,490 | — | — | Number ofSharesBeneficiallyOwned; —; —; —; — |
| All executive officers and directors as a group (12 persons)Beneficial shares | 1,687,208 | — | — | Number ofSharesBeneficiallyOwned; —; —; —; — |
| Frazier Life Sciences XI, L.P.Beneficial ownership | — | 21.3%Beneficial | — | Percentage ofSharesBeneficiallyOwned; BeforeOffering |
| Frazier Life Sciences XI, L.P.Beneficial ownership | — | 12.9%Beneficial | — | Percentage ofSharesBeneficiallyOwned; AfterOffering |
| Alamar HoldCo, LLCBeneficial ownership | — | 12.4%Beneficial | — | Percentage ofSharesBeneficiallyOwned; BeforeOffering |
| Alamar HoldCo, LLCBeneficial ownership | — | 7.5%Beneficial | — | Percentage ofSharesBeneficiallyOwned; AfterOffering |
| venBio Global Strategic Fund IV, L.P.Beneficial ownership | — | 14.6%Beneficial | — | Percentage ofSharesBeneficiallyOwned; BeforeOffering |
| venBio Global Strategic Fund IV, L.P.Beneficial ownership | — | 8.8%Beneficial | — | Percentage ofSharesBeneficiallyOwned; AfterOffering |
| Entities affiliated with Goldman Sachs & Co. LLCBeneficial ownership | — | 9.3%Beneficial | — | Percentage ofSharesBeneficiallyOwned; BeforeOffering |
| Entities affiliated with Goldman Sachs & Co. LLCBeneficial ownership | — | 5.7%Beneficial | — | Percentage ofSharesBeneficiallyOwned; AfterOffering |
| Deep Track Biotechnology Master Fund, LtdBeneficial ownership | — | 7.5%Beneficial | — | Percentage ofSharesBeneficiallyOwned; BeforeOffering |
| Deep Track Biotechnology Master Fund, LtdBeneficial ownership | — | 4.5%Beneficial | — | Percentage ofSharesBeneficiallyOwned; AfterOffering |
| Tao FuBeneficial ownership | — | 3.4%Beneficial | — | Percentage ofSharesBeneficiallyOwned; BeforeOffering |
| Tao FuBeneficial ownership | — | 2.1%Beneficial | — | Percentage ofSharesBeneficiallyOwned; AfterOffering |
| All executive officers and directors as a group (12 persons)Beneficial ownership | — | 6.3%Beneficial | — | Percentage ofSharesBeneficiallyOwned; BeforeOffering; —; —; —; — |
| All executive officers and directors as a group (12 persons)Beneficial ownership | — | 3.9%Beneficial | — | Percentage ofSharesBeneficiallyOwned; AfterOffering; —; —; —; — |
| Frazier Life Sciences XI, L.P.Ownership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition |
| venBio Global Strategic Fund IV, L.P.Ownership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition |
| West Street Life Sciences I, LP, WSLS Offshore Investments, SLP, WSLS Emp Onshore Investments, L.P., WSLS Emp Offshore Investments, L.P. and Broad Street Principal Investments LLC, together with their affiliatesOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition |
| Frazier Life Sciences XI, L.P.Ownership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition |
| venBio Global Strategic Fund IV, L.P.Ownership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition |
| Deep Track Biotechnology Master Fund, LtdOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition |
| Frazier Life Sciences XI, L.P.Ownership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition |
| venBio Global Strategic Fund IV, L.P.Ownership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition |
| West Street Life Sciences I, LP, WSLS Offshore Investments, SLP, WSLS Emp Onshore Investments, L.P., WSLS Emp Offshore Investments, L.P. and Broad Street Principal Investments LLC, together with their affiliatesOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition |
| entities with which certain of our directors are affiliatedOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding common stock; not an additive ownership partition |
| individuals and entities associated with Fenwick & West LLPOwnership as disclosed | — | <0.001%Beneficial | — | Source statement; <; source predicate: beneficially own; primary source clause; full source conditions retained; source scope: of our common stock; not an additive ownership partition |
| common stockper-share voting rights | — | — | 1 vote per shareVotes per share | Literal source per-share voting entitlement; common stock; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section applies at the stated completion/consummation stage of this offering; certificate/bylaw effectiveness conditions remain applicable |
Source and calculation ↗
Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition
Raw source column: Number ofSharesBeneficiallyOwned; source holder: Frazier Life Sciences XI, L.P.(1)
Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition
Raw source column: Number ofSharesBeneficiallyOwned; source holder: Alamar HoldCo, LLC(2)
Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition
Raw source column: Number ofSharesBeneficiallyOwned; source holder: venBio Global Strategic Fund IV, L.P.(3)
Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition
Raw source column: Number ofSharesBeneficiallyOwned; source holder: Entities affiliated with Goldman Sachs & Co. LLC(4)
Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition
Raw source column: Number ofSharesBeneficiallyOwned; source holder: Deep Track Biotechnology Master Fund, Ltd(5)
Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition
Raw source column: Number ofSharesBeneficiallyOwned; source holder: Tao Fu(6)
Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition
Raw source column: Number ofSharesBeneficiallyOwned; source holder: Petter Veiby(7)
Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition
Raw source column: Number ofSharesBeneficiallyOwned; source holder: Hubert Chen(8)
Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition
Raw source column: Number ofSharesBeneficiallyOwned; source holder: Mitchell Gold(9)
Exact source ownership column: Number ofSharesBeneficiallyOwned; —; —; —; —; holders may overlap; not an additive partition
Raw source column: Number ofSharesBeneficiallyOwned; —; —; —; —; source holder: Angie You(10)
Exact source ownership column: Number ofSharesBeneficiallyOwned; —; —; —; —; holders may overlap; not an additive partition
Raw source column: Number ofSharesBeneficiallyOwned; —; —; —; —; source holder: All executive officers and directors as a group (12 persons)(11)
Exact source ownership column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; holders may overlap; not an additive partition
Raw source column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; source holder: Frazier Life Sciences XI, L.P.(1)
Exact source ownership column: Percentage ofSharesBeneficiallyOwned; AfterOffering; holders may overlap; not an additive partition
Raw source column: Percentage ofSharesBeneficiallyOwned; AfterOffering; source holder: Frazier Life Sciences XI, L.P.(1)
Exact source ownership column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; holders may overlap; not an additive partition
Raw source column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; source holder: Alamar HoldCo, LLC(2)
Exact source ownership column: Percentage ofSharesBeneficiallyOwned; AfterOffering; holders may overlap; not an additive partition
Raw source column: Percentage ofSharesBeneficiallyOwned; AfterOffering; source holder: Alamar HoldCo, LLC(2)
Exact source ownership column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; holders may overlap; not an additive partition
Raw source column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; source holder: venBio Global Strategic Fund IV, L.P.(3)
Exact source ownership column: Percentage ofSharesBeneficiallyOwned; AfterOffering; holders may overlap; not an additive partition
Raw source column: Percentage ofSharesBeneficiallyOwned; AfterOffering; source holder: venBio Global Strategic Fund IV, L.P.(3)
Exact source ownership column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; holders may overlap; not an additive partition
Raw source column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; source holder: Entities affiliated with Goldman Sachs & Co. LLC(4)
Exact source ownership column: Percentage ofSharesBeneficiallyOwned; AfterOffering; holders may overlap; not an additive partition
Raw source column: Percentage ofSharesBeneficiallyOwned; AfterOffering; source holder: Entities affiliated with Goldman Sachs & Co. LLC(4)
Exact source ownership column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; holders may overlap; not an additive partition
Raw source column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; source holder: Deep Track Biotechnology Master Fund, Ltd(5)
Exact source ownership column: Percentage ofSharesBeneficiallyOwned; AfterOffering; holders may overlap; not an additive partition
Raw source column: Percentage ofSharesBeneficiallyOwned; AfterOffering; source holder: Deep Track Biotechnology Master Fund, Ltd(5)
Exact source ownership column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; holders may overlap; not an additive partition
Raw source column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; source holder: Tao Fu(6)
Exact source ownership column: Percentage ofSharesBeneficiallyOwned; AfterOffering; holders may overlap; not an additive partition
Raw source column: Percentage ofSharesBeneficiallyOwned; AfterOffering; source holder: Tao Fu(6)
Exact source ownership column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; —; —; —; —; holders may overlap; not an additive partition
Raw source column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; —; —; —; —; source holder: All executive officers and directors as a group (12 persons)(11)
Exact source ownership column: Percentage ofSharesBeneficiallyOwned; AfterOffering; —; —; —; —; holders may overlap; not an additive partition
Raw source column: Percentage ofSharesBeneficiallyOwned; AfterOffering; —; —; —; —; source holder: All executive officers and directors as a group (12 persons)(11)
Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition
Consists of shares of our Series A Preferred Stock purchased by Frazier Life Sciences XI, L.P., which beneficially owns more than 5% of our outstanding capital stock. James Topper, a member of our board of directors, is affiliated with Frazier Life Sciences XI, L.P.
Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition
Consists of shares of our Series A Preferred Stock purchased by venBio Global Strategic Fund IV, L.P., which beneficially owns more than 5% of our outstanding capital stock. Aaron Royston, a member of our board of directors, is affiliated with venBio Global Strategic Fund IV, L.P.
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition
Consists of shares of our Series B Preferred Stock purchased by West Street Life Sciences I, LP, WSLS Offshore Investments, SLP, WSLS Emp Onshore Investments, L.P., WSLS Emp Offshore Investments, L.P. and Broad Street Principal Investments LLC, which together with their affiliates, hold more than 5% of our outstanding capital stock. Colin Walsh, a member of our board of directors, is affiliated with Goldman Sachs & Co. LLC.
Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition
Consists of shares of our Series B Preferred Stock purchased by Frazier Life Sciences XI, L.P., which beneficially owns more than 5% of our outstanding capital stock. James Topper, a member of our board of directors, is affiliated with Frazier Life Sciences XI, L.P.
Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition
Consists of shares of our Series B Preferred Stock purchased by venBio Global Strategic Fund IV, L.P., which beneficially owns more than 5% of our outstanding capital stock. Aaron Royston, a member of our board of directors, is affiliated with venBio Global Strategic Fund IV, L.P.
Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition
Consists of shares of our Series C Preferred Stock purchased by Deep Track Biotechnology Master Fund, Ltd, which beneficially owns more than 5% of our outstanding capital stock. Rebecca Luse, a former member of our board of directors, is affiliated with Deep Track Biotechnology Master Fund, Ltd. Ms. Luse resigned from our board of directors immediately prior to the effectiveness of the registration statement of which this prospectus forms a part.
Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition
Consists of shares of our Series C Preferred Stock purchased by Frazier Life Sciences XI, L.P., which beneficially owns more than 5% of our outstanding capital stock. James Topper, a member of our board of directors, is affiliated with Frazier Life Sciences XI, L.P.
Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition
Consists of shares of our Series C Preferred Stock purchased by venBio Global Strategic Fund IV, L.P., which beneficially owns more than 5% of our outstanding capital stock. Aaron Royston, a member of our board of directors, is affiliated with venBio Global Strategic Fund IV, L.P.
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition
Consists of shares of our Series C Preferred Stock purchased by West Street Life Sciences I, LP, WSLS Offshore Investments, SLP, WSLS Emp Onshore Investments, L.P., WSLS Emp Offshore Investments, L.P. and Broad Street Principal Investments LLC, which together with their affiliates, hold more than 5% of our outstanding capital stock. Colin Walsh, a member of our board of directors, is affiliated with Goldman Sachs & Co. LLC.
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding common stock; not an additive ownership partition
In connection with our Series C Preferred Stock financing, we entered into the IRA with certain holders of our redeemable convertible preferred stock, including entities with which certain of our directors are affiliated and who hold more than 5% of our outstanding common stock. Under the IRA, these stockholders are entitled to rights with respect to the registration of their shares under the Securities Act following this offering, and the registration rights provisions included in the IRA will not terminate as a result of this offering. See the section titled “Description of Capital Stock—Registration Rights” for additional information.
Source statement; <; source predicate: beneficially own; primary source clause; full source conditions retained; source scope: of our common stock; not an additive ownership partition
The validity of the shares of our common stock offered by this prospectus will be passed upon for us by Fenwick & West LLP, San Francisco, California. As of the date of this prospectus, individuals and entities associated with Fenwick & West LLP beneficially own an aggregate of less than 0.001% of our common stock. Cooley LLP, San Diego, California is acting as counsel for the underwriters in connection with this offering.
Literal source per-share voting entitlement; common stock; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section applies at the stated completion/consummation stage of this offering; certificate/bylaw effectiveness conditions remain applicable
Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. We have not provided for cumulative voting for the election of directors in our restated certificate of incorporation, which means that holders of a majority of the shares of our common stock will be able to elect all of our directors. Our restated certificate of incorporation will establish a classified board of directors, to be divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Source context: The following description summarizes the most important terms of our capital stock, as will be in effect following this offering. Because it is only a summary, it does not contain all the information that may be important to you. We expect to adopt a restated certificate of incorporation and restated bylaws that will become effective immediately prior to the completion of this offering, and this description summarizes provisions that are expected to be included in these documents. For a complete description, you should refer to our restated certificate of incorporation and restated bylaws, which are included as exhibits to the registration statement of which this prospectus forms a part, and to the applicable provisions of Delaware law.
Saved control snapshot
The dated saved report retains its own figures and assumptions. These strings are not new calculation inputs.
| Holder / measure | Shares | Ownership | Voting rights | Reference |
|---|---|---|---|---|
| Existing holdersMajor ownership group | — | ~60.5%* | — | |
| Other disclosed classesMajor ownership group | — | See filing | — | |
| IPO sharesPublic / new investors | — | 17.000M | — |
Economic ownership
A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.
IPO shares are immediately tradable; later supply depends on the final lock-up, option and resale-registration terms.
- Initial float
- 17.000M
- Restricted / potential supply
- 43.03M
- Multiple
- See filing
- Increase
- See filing
Share supply
Source lock-up conditions
Literal day restriction; after date of this prospectus; full conditions and exceptions remain in the source paragraph
| Measure | Reported value |
|---|---|
| We, our officers, directors and all of our stockholdersAfter date of this prospectus · Source conditions apply | 180 days |
| Each of our officers, directors and all of our stockholdersAfter date of this prospectus · Source conditions apply | 180 days |
Source and calculation
We, our officers, directors and all of our stockholders have agreed with the underwriters that for a period of 180 days, after the date of this prospectus, among other things and subject to certain exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to sell, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock, or publicly declare an intention to do any of the foregoing. Upon expiration of the lock-up period, certain of our stockholders will have the right to require us to register their shares under the Securities Act. See the subsection titled “Registration Rights” below and the section titled “Description of Capital Stock—Registration Rights.”
SEC lock-up paragraph; source 1533482:1534829; SHA256 8122d6937abadac01ad2b04cd9a3dfb34465ef286277ea82e2c3670b323d8c03 ↗Based on 26,029,017 shares of our common stock outstanding as of March 31, 2026, including the automatic conversion of all shares of our outstanding redeemable convertible preferred stock as of March 31, 2026 into an aggregate of 21,517,976 shares of our common stock in connection with the completion of this offering, upon completion of this offering, we will have a total of 43,029,017 shares of common stock outstanding. Of these shares, only the 17,000,000 shares of common stock sold in this offering, or 19,550,000 shares if the underwriters exercise their option to purchase additional shares in full, will be freely tradable, without restriction, in the public market immediately after this offering. Each of our officers, directors and all of our stockholders have entered into lock-up agreements with the underwriters that, among other things and subject to certain exceptions, restrict their ability to sell or transfer their shares. The lock-up agreements pertaining to this offering will expire 180 days from the date of this prospectus. However, Morgan Stanley & Co. LLC, Leerink Partners LLC, Citigroup Global Markets Inc. and RBC Capital Markets, LLC may, in their sole discretion, permit our officers, directors and other stockholders to sell shares prior to the expiration of the lock-up agreements. After the lock-up agreements expire, based on 26,029,017 shares outstanding as of March 31, 2026, approximately up to an additional 26,749,461 shares of common stock will be eligible for sale in the public market, approximately 15,044,561 of which shares are held by our officers, directors and their affiliated entities, and will be subject to volume limitations under Rule 144 under the Securities Act.
SEC lock-up paragraph; source 603838:605892; SHA256 a4ad8713f59e1bfee1a61ae636aefa36ab2b70bbdc4de2785c5217d2ea04c0a6 ↗Conditional lock-up timeline
Conditional lock-up timeline
Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.
Milestones and unconfirmed releases
| Holder / event | Term / date | Conditions |
|---|---|---|
| Over-allotment window | Post-listing See filing · Additional shares only if exercised | Over-allotment window · Additional shares only if exercised |
| Insider resale eligibility | Holder-specific See 424B · Existing-holder supply | Insider resale eligibility · Existing-holder supply |
Basis and evidence
Over-allotment window · Additional shares only if exercised
Lock-up / shares eligible for future sale ↗Insider resale eligibility · Existing-holder supply
Lock-up / shares eligible for future sale ↗Financial quality
Bars compare absolute amounts within each measure. Each measure has its own scale.
Net income / (loss)
$ · Annual values as reported · ConsolidatedOperating cash flow
$ · Annual values as reported · Consolidated| Calculation | Reported value |
|---|---|
| Cash and cash equivalents2024-12-31 · Consolidated | $30,632,000 |
| Cash and cash equivalents2025-12-31 · Consolidated | $40,193,000 |
| Current assets2024-12-31 · Consolidated | $72,482,000 |
| Current assets2025-12-31 · Consolidated | $156,295,000 |
| Total assets2024-12-31 · Consolidated | $76,716,000 |
| Total assets2025-12-31 · Consolidated | $165,893,000 |
| Current liabilities2024-12-31 · Consolidated | $7,722,000 |
| Current liabilities2025-12-31 · Consolidated | $11,007,000 |
| Total liabilities2024-12-31 · Consolidated | $14,588,000 |
| Total liabilities2025-12-31 · Consolidated | $15,103,000 |
| Total equity / (deficit)2024-12-31 · Consolidated | ($46,825,000) |
| Total equity / (deficit)2025-12-31 · Consolidated | ($107,436,000) |
| RevenueFY2025 · Consolidated | $1,350,000 |
| Net income / (loss)FY2024 · Consolidated | ($39,801,000) |
| Net income / (loss)FY2025 · Consolidated | ($60,627,000) |
| Operating cash flowFY2024 · Consolidated | ($35,035,000) |
| Operating cash flowFY2025 · Consolidated | ($59,199,000) |
| Cash and cash equivalents2025-12-31 · Consolidated · Unaudited | $40,193,000 |
| Cash and cash equivalents2026-03-31 · Consolidated · Unaudited | $43,297,000 |
| Current assets2025-12-31 · Consolidated · Unaudited | $156,295,000 |
| Current assets2026-03-31 · Consolidated · Unaudited | $136,642,000 |
| Total assets2025-12-31 · Consolidated · Unaudited | $165,893,000 |
| Total assets2026-03-31 · Consolidated · Unaudited | $146,086,000 |
| Current liabilities2025-12-31 · Consolidated · Unaudited | $11,007,000 |
| Current liabilities2026-03-31 · Consolidated · Unaudited | $9,799,000 |
| Total liabilities2025-12-31 · Consolidated · Unaudited | $15,103,000 |
| Total liabilities2026-03-31 · Consolidated · Unaudited | $13,375,000 |
| Total equity / (deficit)2025-12-31 · Consolidated · Unaudited | ($107,436,000) |
| Total equity / (deficit)2026-03-31 · Consolidated · Unaudited | ($125,515,000) |
| Net income / (loss)3M ended 2025-03-31 · Consolidated · Unaudited | ($15,151,000) |
| Net income / (loss)3M ended 2026-03-31 · Consolidated · Unaudited | ($18,656,000) |
| Operating cash flow3M ended 2025-03-31 · Consolidated · Unaudited | ($14,131,000) |
| Operating cash flow3M ended 2026-03-31 · Consolidated · Unaudited | ($18,141,000) |
Basis and evidence
Saved snapshot — period not verified
These saved figures have no verified reporting period or currency basis. They are excluded from statement comparisons and calculations.
Financial quality
| Calculation | Reported value | Reference |
|---|---|---|
| Revenue | $1.35M | Not meaningful |
| Net result | $(64.13M) | Latest reported |
| Market-value reference | $895.00M | Post-listing snapshot |
| Shares outstanding | 43.03M | Latest reported |
| Offer size | $289.00M | 17.000M |
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Financial review | Reported financial figures are shown above. A cash-runway estimate needs compatible cash-flow and funding assumptions. Open filing ↗ |
Baseline filing — comparison pending
No source-comparable material changes identified in this report.
Why it mattersChanges dilution, public float and potential supply.
Evidence · 424B4 · 2026/08/05Why it mattersChanges valuation, proceeds and first-day return assumptions.
Evidence · 424B4 · 2026/08/05424B4
• Final prospectus source verified
• Trading began on 2026-08-05 at $17.00
Clinical development, regulatory approval and cash-runway outcomes can change the equity value materially.
- Potential impact
- High
- Evidence
- 424B4 · 2026/08/05 ↗
The latest reported period remains loss-making.
- Potential impact
- High
- Evidence
- 424B4 · 2026/08/05 ↗
The primary-secondary mix, controlling holders and voting rights require the final beneficial-ownership table.
- Potential impact
- High
- Evidence
- 424B4 · 2026/08/05 ↗
Option exercise, employee equity and lock-up expiry can expand tradable supply.
- Potential impact
- Medium
- Evidence
- 424B4 · 2026/08/05 ↗
Sources and calculation notes
Final prospectus, offer price, listing date and headline financial evidence reconciled
View the filing's actual first page +
